NCT03080311View on ClinicalTrials.gov

A Study of APG-1252 in Patients With SCLC or Other Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

February 12, 2017

Primary Completion Date

June 22, 2020

Study Completion Date

July 17, 2020

Conditions
Small Cell Lung CancerSolid Tumor
Interventions
DRUG

APG-1252

Multiple dose cohorts, 30 minute IV infusion, twice weekly for 3 weeks of a cycle with 28 days.

Trial Locations (2)

49503

START Midwest, Grand Rapids

78229

The START Center for Cancer Care, San Antonio

Sponsors
All Listed Sponsors
lead

Ascentage Pharma Group Inc.

INDUSTRY